C.Surgical ProcedurePhase 4SICSNCT02798068
Steroids and Microcirculation In Cardiac Surgery
A Phase 4 study of C.Surgical Procedure and Cardiac, run by Erasme University Hospital at 1 site in Belgium.
Trial summary
Cardiac surgery is sometimes associated with organ dysfunction of variable severity (renal insufficiency, cognitive decline, arrhythmias, ARDS). The phenomenon responsible is an intense inflammatory reaction induced by cardiopulmonary bypass, leading to microcirculation alterations, specially in endothelial cell and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- C.Surgical Procedure, Cardiac
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteBelgium
- Study dates
- May 2016to Sep 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients eligible for cardiac surgery
Who cannot join
- Age under 18years
- Allergy to corticoids
- Extreme emergency surgery
- Upper member vascular disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1)
Cardiac surgery is sometimes associated with organ dysfunction of variable severity (renal insufficiency, cognitive decline, arrhythmias, ARDS). The phenomenon responsible is an intense inflammatory reaction induced by cardiopulmonary bypass, leading to microcirculation alterations, specially in endothelial cell and its protective layer - glycocalyx. Endothelial dysfunction then reduces the reactivity of peripheral tissues to hypoxia, and is associated with bad prognosis.
High - dose corticoids administration at anesthesia induction in cardiac surgery could attenuate the intensity of this inflammatory reaction, and represents the current practice in our hospital. Nevertheless, this attitude is abandoned in numerous cardiac surgery centres.
Read the detailed description
Introduction Cardiac surgery is associated with variable severity organ dysfunction, which further leads to an increase of ICU length of stay (ICU LOS) or even higher mortality. Various mecanisms enter into account, from global through regional hemodynamics until microcirculation alterations.
These are due to an intense inflammatory reaction triggered by the contact of blood with cardiopulmonary bypass surfaces, the contact blood - air from cardiotomy aspiration, heparin and heparin - protamin complexes, ischemia - reperfusion mediators, and toxins from the digestive tube.
These alterations are observed in both the beating heart surgery and surgery with cardiopulmonary bypass (CBP). The inflammatory response is probably less important in off - pump surgery though this is hypothesis often questionned and some publications show that the changes associated with CBP could only be transient.
Inflammatory response is possibly reduced by high - dose corticoid administration at anesthesia induction - by preserving cell membrane integrity, leucocyte adhesion and cellular immunity attenuation, and finally by complement and cytokine release reduction.
Numerous metaanalyses show benefits of this strategy with an acceptable security profile:
- Atrial fibrillation reduction
- Possible ICU LOS reduction
- Same incidence of wound infection
Within the risks can be observed:
- Higher incidence of hyperglycemia
- No impact on overall mortality However, two recent big RCTs did not find any benefit as in terms of morbidity-mortality, incidence of wound infection and possibly an increase in number of reinterventions for tamponnade.
Providing the low level of evidence on real benefits and some of the secondary effects, the systematic use of corticoids (as applied in our centre) was abandonned by a some of cardiac surgery centres.
Nevertheless, corticoids could be beneficial in specific subgroups. In order to identify these patients, it is important to understand the mecanism of microcirculation alterations in the setting of cardiac surgery with CBP and the effect of corticoids on CBP induced inflammatory processes.
The alterations of endothelial function under CBP may be observed at three levels :
- endothelial reactivity (vasodilation et vasoconstriction)
- blood flow (acceleration et deceleration)
- glycocalyx (endothelial protective layer) These three components of microcirculation are tightly linked. De Backer study on sublingual microcirculation shows its alterations specific for this type of surgery (more pronounced in cardiac surgery with CBP than off-pump) and not found in minor surgery (thyroidectomy). He also found a positive correlation with lactate level. Cardiac surgery can be considered as an interesting microcirculation and endothelial function study model.
The hypothesis of investigators is that microcirculation modifications along with those of endothelial function in cardiac surgery with CBP are due to endothelial cell impairement and impairement of its protective layer - glycocalyx, condition which deregulates the peripheral tissue reactivity to hypoxia, and that corticoids could reduce these alterations.
The investigators will study the endothelial function by three methods :
A/ FMD (Flow Mediated vasoDilation) which is a non invasive technique considered as the gold standard for endothelial reactivity evaluation since the end of 1990s. It is based on echographic measurement of brachial artery diameter variation and the Doppler flow evaluation, during an episode of transient ischemia induced by pneumatic cuff inflation (vascular occlusion test).
Three studies showed a reversible alteration of endothelial function mainly after cardiac surgery using CBP with continuous blood flow (FMD variation of about 11%). Expecting a reduction of endothelial dysfunction with corticoids by 5%, the investigators will analyze a group of 60 patients (30 in the corticoids group and 30 in the placebo group). In previous studies, variation is already significative when FMD varies from 1,5 - 2%.
B/ NIRS (near infrared spectroscopy) - it's a non invasive technique which measures peripheral tissue oxygen saturation and allows to assess oxygen consumption and microcirculation reactivity during an arterial occlusion test distally to compressive cuff.
Alterations of the variables derived from delta StO2 (peripheral tissue oxygen saturation) after an ischemic - reperfusion event, rather than absolute value of StO2 are predictive of bad prognosis in a septic patient or in severe head injury. These variables are delta StO2, HbT (total tissue hemoglobin) and THI (muscular hemoglobin index). From these elements can be calculated others: RdecStO2 (StO2 decrease rate during ischemic event reflecting the tissue oxygen consumption) and RincStO2 (increase rate of StO2 during the reperfusion phase, corresponding to relative hyperemia). Both are expressed in %/s. The intensity of reperfusion can be quantified by delta THI.
A recent study in cardiac surgery did not show StO2 modifications under CBP but providing a small population sample and the type of monitoring used, this study might include some methodologic biais.
Finally, very recently a correlation between FMD and the variation of NIRS during a vascular occlusion test has been found in a young healthy subject, which only confirms the influence of endothelial function onto microcirculation.
C/ Syndecan - 1 concentration assessment: This molecule is closely linked to glycocalyx and is considered as the most predictive marker of its integrity.
Many factors might cause lesions of this structure (inflammation, hyperglycemia, CBP, etc). Its destruction causes further an impairement of endothelial function (vasoconstriction et vasodilation), mediated principally by endothelial factors.
Corticoids can be considered as the most effective molecule for glycocalyx protection.
Yet the investigators will analyze syndecan - 1 as a glycocalyx marker.
Material and methods :
After ethics commitee approbation and signed informed consent obtention, the investigators will enroll 60 patients scheduled for cardiac surgery with CBP (aorto - coronary bypass graft or valve replacement).
Patients randomized in the Corticoids group will receive 500mg of methylprednisolone in 100ml of NaCl 0,9% at anesthesia induction, Placebo group will receive 100ml of NaCl 0,9% - both solutions are prepared at the hospital pharmacy and only the pharmacist knows the preparation content (double blinding).
Exclusion criteria are age under 18, extreme emergency surgery if the testing would slow down the surgical treatment. The investigators also exclude the patients where the placement of pneumatic cuff would be impossible (amputation, AV fistula)
Anesthesia procedure:
All the patients receive the same anesthesia technique, based on propofol and remifentanil at objective of concentration. Relaxation is achieved by cisatracurium in continuous infusion. This type of anesthesia is the current practice in Erasme hospital. All the patients are equipped with radial artery catheter and central venous catheter, the use of pulmonary artery catheter is left to anesthetist's discretion.
Before starting the CBP, all patients receive heparin with target ACT (activated clotting time) above 480seconds. The priming of CBP consists on 500ml of gelatin (Geloplasma, Fresenius), with 500ml of cristaloids (Plasmalyte, Baxter) and 200ml of mannitol (Mannitol 15%, Baxter). Cardioplegy is achieved by blood infusion (T 36°) with potassium chloride. The CBP flow is continuous of 2.4L/m2 and mean arterial pressure is maintened between 60 and 90 mm Hg. Glycemia is controlled strictly from the moment of anesthesia induction by short acting insulin administrered continuously.
All patients are transferred to ICU after the surgery, sedated with propofol and remifentanyl until hemodynamic stability and absence of bleeding is achieved. Sedation is then stopped and patient is extubated.
Vascular occlusion test:
Arterial diameter variation and Doppler flow are measured at brachial artery above medial epicondyl, proximally to the pneumatic cuff placed at forearm. For echography analysis, a linear probe of 12 MHz will be used, held by a metallic support to allow more precision and better reproducibility. After initial diameter measurement, pneumatic cuff 50 mmHg will be inflated above the arterial pressure of the patient during 5minutes, in order to induce ischemia. Diameter variations in brachial artery are measured continuously from 30 secondes before releasing of the cuff until 3 minutes afterwards. FMD is evaluated by following parameters : baseline diameter and maximal FMD variation in pourcents. In numerous studies, FMD is calculated using the formula: FMD (%) = ([diametre of maximal dilation after cuff release - baseline diametre]/ baseline diametre) x 100. In order to reduce variability of the measrure, diameter variation will be adjusted to baseline diameter and to initiating stimulus assessed by Doppler flow. Data will be stocked and analyzed by Quipu FMD.
StO2 is measured by tissular spectrometer (Invos, Covidien) consisting of a photodetector, processor and a 15 mm optic probe. This proble is placed over thenar eminence of the arm without any IV line. StO2 is enregistered every 2 secondes.
Practically, after performing the initial echographic measurements, and after 3 minutes of stabilisation of StO2 (baseline), an ischemic event of 5 minutes is created by a fast pneumatic cuff inflation to a value of 50mmHg above patients systemic blood pressure. This will stop arterial and venous blood flow in the forearm, leading to a decrease of HbO2 (= rate of decrease StO2 (%/s)).
After 5 minutes the cuff will be rapidly deflated (<1seconds) inducing arterial diameter and flow increase - the variation is assessed by echography and Doppler. At the same time, StO2 increases (= StO2 increase rate (%/s)) and achieves higher values than baseline (= reactive hyperemia = delta diametre, flow velocity and StO2). The NIRS device measures also THi (tissular hemoglobin index) at baseline and 1 minute, its minimum et maximum.
The increase rate of arterial diameter reflects endothelial reactivity while StO2 increase rate is considered as a tissue = hemoglobin flow marker. Reactive hyperemia can be interpreted as a test of microcirculation reactivity. Rate of StO2 decrease/THi is considered as oxygen consumption marker.
Syndecan-1 analysis is performed on frozen plasma by ELISA technique, using specific antibodies (ELISA kit from Ray Biotech, Inc), this method has already been used in previous studies.
Timing of measurements:
Measures are performed on the day before surgery, at the ICU admission, at 24h and at the day 7 of hospital stay.
Glycocalyx function assessment:
The first analysis will be performed on the day before surgery, then after anesthesia induction, at ICU admission, at 24h and 48h.
- Conditions
- C.Surgical Procedure, Cardiac
- Being tested
- Solu-medrol or placebo administration
- Keywords
- Steroids, Cardiac surgery, Endothelial dysfunction, Glycocalyx, Flow mediated vasodilation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Solu-medrol or placebo administrationDrug
Also called Solu-medrol 500mg IV BE145214, Solu-medrol 500mg IV H02AB04, Solu-medrol 500mg IV SUB14562MIG, Solu-medrol 500mg IV 277S102F12
patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
| Study group | Role | What they receive |
|---|---|---|
| Solu - Medrol | Active comparator | Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration Receives: Drug: Solu-medrol or placebo administration |
| Placebo | Placebo comparator | NaCl 0,9% 100ml IV once single administration Receives: Drug: Solu-medrol or placebo administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Flow Mediated Vasodilation change
Arterial diameter variation and Doppler flow are measured at brachial artery during vascular occlusion test - viariation of diameter and doppler flow befor and after cuff release will be assessed
Measured: 3 measurements of 5 minutes each - vascular occlusion test once daily during 48h.
Secondary outcomes (1)
StO2 variation change
Tissue oxygen saturation will be assessed by near - infrared spectroscopy (physiological parameter assesment based on spectrophotometry) during vascular occlusion test and after cuff release
Measured: 4 measurements of 5 minutes each - vascular occlusion test test once daily during 48h
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2016 (estimated)
- Study startMay 2016
- Primary completionSep 2021
- Study completionSep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (27)Papers the sponsor has linked to this study.
- Other trials for C.Surgical ProcedureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erasme University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Luc Van Obbergh, Pr, Study chair, Anesthesia Department Hôpital Erasme
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02798068
- Sponsor's protocol ID
- P2016/017
- Acronym
- SICS
- Status last verified
- Sep 2021
- First submitted
- 25 May 2016
- Last updated
- 1 Jul 2024
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Patila T, Kukkonen S, Vento A, Pettila V, Suojaranta-Ylinen R. Relation of the Sequential Organ Failure Assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg. 2006 Dec;82(6):2072-8. doi: 10.1016/j.athoracsur.2006.06.025.
PubMed 17126112Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997 Sep;112(3):676-92. doi: 10.1378/chest.112.3.676.
PubMed 9315800Riddington DW, Venkatesh B, Boivin CM, Bonser RS, Elliott TS, Marshall T, Mountford PJ, Bion JF. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA. 1996 Apr 3;275(13):1007-12.
PubMed 8596232Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg. 1998 Feb;65(2):420-4. doi: 10.1016/s0003-4975(97)01127-2.
PubMed 9485239Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):384-93. doi: 10.1053/j.jvca.2008.09.007. Epub 2008 Dec 3. No abstract available.
PubMed 19054695Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J. 2008 Nov;29(21):2592-600. doi: 10.1093/eurheartj/ehn333. Epub 2008 Jul 28.
PubMed 18664462Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth. 2011 Feb;25(1):156-65. doi: 10.1053/j.jvca.2010.03.015. Epub 2010 May 26.
PubMed 20537923Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum A, Quantz M, Tagarakis GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S; SIRS Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Sep 26;386(10000):1243-1253. doi: 10.1016/S0140-6736(15)00273-1.
PubMed 26460660van Osch D, Dieleman JM, Nathoe HM, Boasson MP, Kluin J, Bunge JJ, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, de Lange F, Boer C, van Dijk D; Dexamethasone for Cardiac Surgery Study Group. Intraoperative High-Dose Dexamethasone in Cardiac Surgery and the Risk of Rethoracotomy. Ann Thorac Surg. 2015 Dec;100(6):2237-42. doi: 10.1016/j.athoracsur.2015.06.025. Epub 2015 Aug 25.
PubMed 26319483De Backer D, Dubois MJ, Schmartz D, Koch M, Ducart A, Barvais L, Vincent JL. Microcirculatory alterations in cardiac surgery: effects of cardiopulmonary bypass and anesthesia. Ann Thorac Surg. 2009 Nov;88(5):1396-403. doi: 10.1016/j.athoracsur.2009.07.002.
PubMed 19853081Alley H, Owens CD, Gasper WJ, Grenon SM. Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. J Vis Exp. 2014 Oct 22;(92):e52070. doi: 10.3791/52070.
PubMed 25406739Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. doi: 10.1016/s0735-1097(01)01746-6.
PubMed 11788217Sangalli F, Guazzi M, Senni S, Sala W, Caruso R, Costa MC, Formica F, Avalli L, Fumagalli R. Assessing Endothelial Responsiveness After Cardiopulmonary Bypass: Insights on Different Perfusion Modalities. J Cardiothorac Vasc Anesth. 2015 Aug;29(4):912-6. doi: 10.1053/j.jvca.2014.11.008. Epub 2014 Nov 11.
PubMed 25661644De Backer D, Durand A. Monitoring the microcirculation in critically ill patients. Best Pract Res Clin Anaesthesiol. 2014 Dec;28(4):441-51. doi: 10.1016/j.bpa.2014.09.005. Epub 2014 Sep 28.
PubMed 25480773Cohn SM, Nathens AB, Moore FA, Rhee P, Puyana JC, Moore EE, Beilman GJ; StO2 in Trauma Patients Trial Investigators. Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation. J Trauma. 2007 Jan;62(1):44-54; discussion 54-5. doi: 10.1097/TA.0b013e31802eb817.
PubMed 17215732
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1)
- ClinicalTrials.gov ID
- NCT02798068
- Acronym / sponsor ID
- SICS / P2016/017
- Conditions
- C.Surgical Procedure, Cardiac
- Keywords
- Steroids, Cardiac surgery, Endothelial dysfunction, Glycocalyx, Flow mediated vasodilation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Erasme University HospitalUniversity, hospital or other
- Study start
- May 2016
- Primary completion
- Sep 2021 (actual)
- Study completion
- Sep 2021 (actual)
- First posted
- 14 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cardiac surgery is sometimes associated with organ dysfunction of variable severity (renal insufficiency, cognitive decline, arrhythmias, ARDS). The phenomenon responsible is an intense inflammatory reaction induced by cardiopulmonary bypass, leading to microcirculation alterations, specially in endothelial cell and its protective layer - glycocalyx. Endothelial dysfunction then reduces the reactivity of peripheral tissues to hypoxia, and is associated with bad prognosis.
High - dose corticoids administration at anesthesia induction in cardiac surgery could attenuate the intensity of this inflammatory reaction, and represents the current practice in our hospital. Nevertheless, this attitude is abandoned in numerous cardiac surgery centres.
Detailed description
Introduction Cardiac surgery is associated with variable severity organ dysfunction, which further leads to an increase of ICU length of stay (ICU LOS) or even higher mortality. Various mecanisms enter into account, from global through regional hemodynamics until microcirculation alterations.
These are due to an intense inflammatory reaction triggered by the contact of blood with cardiopulmonary bypass surfaces, the contact blood - air from cardiotomy aspiration, heparin and heparin - protamin complexes, ischemia - reperfusion mediators, and toxins from the digestive tube.
These alterations are observed in both the beating heart surgery and surgery with cardiopulmonary bypass (CBP). The inflammatory response is probably less important in off - pump surgery though this is hypothesis often questionned and some publications show that the changes associated with CBP could only be transient.
Inflammatory response is possibly reduced by high - dose corticoid administration at anesthesia induction - by preserving cell membrane integrity, leucocyte adhesion and cellular immunity attenuation, and finally by complement and cytokine release reduction.
Numerous metaanalyses show benefits of this strategy with an acceptable security profile:
- Atrial fibrillation reduction
- Possible ICU LOS reduction
- Same incidence of wound infection
Within the risks can be observed:
- Higher incidence of hyperglycemia
- No impact on overall mortality However, two recent big RCTs did not find any benefit as in terms of morbidity-mortality, incidence of wound infection and possibly an increase in number of reinterventions for tamponnade.
Providing the low level of evidence on real benefits and some of the secondary effects, the systematic use of corticoids (as applied in our centre) was abandonned by a some of cardiac surgery centres.
Nevertheless, corticoids could be beneficial in specific subgroups. In order to identify these patients, it is important to understand the mecanism of microcirculation alterations in the setting of cardiac surgery with CBP and the effect of corticoids on CBP induced inflammatory processes.
The alterations of endothelial function under CBP may be observed at three levels :
- endothelial reactivity (vasodilation et vasoconstriction)
- blood flow (acceleration et deceleration)
- glycocalyx (endothelial protective layer) These three components of microcirculation are tightly linked. De Backer study on sublingual microcirculation shows its alterations specific for this type of surgery (more pronounced in cardiac surgery with CBP than off-pump) and not found in minor surgery (thyroidectomy). He also found a positive correlation with lactate level. Cardiac surgery can be considered as an interesting microcirculation and endothelial function study model.
The hypothesis of investigators is that microcirculation modifications along with those of endothelial function in cardiac surgery with CBP are due to endothelial cell impairement and impairement of its protective layer - glycocalyx, condition which deregulates the peripheral tissue reactivity to hypoxia, and that corticoids could reduce these alterations.
The investigators will study the endothelial function by three methods :
A/ FMD (Flow Mediated vasoDilation) which is a non invasive technique considered as the gold standard for endothelial reactivity evaluation since the end of 1990s. It is based on echographic measurement of brachial artery diameter variation and the Doppler flow evaluation, during an episode of transient ischemia induced by pneumatic cuff inflation (vascular occlusion test).
Three studies showed a reversible alteration of endothelial function mainly after cardiac surgery using CBP with continuous blood flow (FMD variation of about 11%). Expecting a reduction of endothelial dysfunction with corticoids by 5%, the investigators will analyze a group of 60 patients (30 in the corticoids group and 30 in the placebo group). In previous studies, variation is already significative when FMD varies from 1,5 - 2%.
B/ NIRS (near infrared spectroscopy) - it's a non invasive technique which measures peripheral tissue oxygen saturation and allows to assess oxygen consumption and microcirculation reactivity during an arterial occlusion test distally to compressive cuff.
Alterations of the variables derived from delta StO2 (peripheral tissue oxygen saturation) after an ischemic - reperfusion event, rather than absolute value of StO2 are predictive of bad prognosis in a septic patient or in severe head injury. These variables are delta StO2, HbT (total tissue hemoglobin) and THI (muscular hemoglobin index). From these elements can be calculated others: RdecStO2 (StO2 decrease rate during ischemic event reflecting the tissue oxygen consumption) and RincStO2 (increase rate of StO2 during the reperfusion phase, corresponding to relative hyperemia). Both are expressed in %/s. The intensity of reperfusion can be quantified by delta THI.
A recent study in cardiac surgery did not show StO2 modifications under CBP but providing a small population sample and the type of monitoring used, this study might include some methodologic biais.
Finally, very recently a correlation between FMD and the variation of NIRS during a vascular occlusion test has been found in a young healthy subject, which only confirms the influence of endothelial function onto microcirculation.
C/ Syndecan - 1 concentration assessment: This molecule is closely linked to glycocalyx and is considered as the most predictive marker of its integrity.
Many factors might cause lesions of this structure (inflammation, hyperglycemia, CBP, etc). Its destruction causes further an impairement of endothelial function (vasoconstriction et vasodilation), mediated principally by endothelial factors.
Corticoids can be considered as the most effective molecule for glycocalyx protection.
Yet the investigators will analyze syndecan - 1 as a glycocalyx marker.
Material and methods :
After ethics commitee approbation and signed informed consent obtention, the investigators will enroll 60 patients scheduled for cardiac surgery with CBP (aorto - coronary bypass graft or valve replacement).
Patients randomized in the Corticoids group will receive 500mg of methylprednisolone in 100ml of NaCl 0,9% at anesthesia induction, Placebo group will receive 100ml of NaCl 0,9% - both solutions are prepared at the hospital pharmacy and only the pharmacist knows the preparation content (double blinding).
Exclusion criteria are age under 18, extreme emergency surgery if the testing would slow down the surgical treatment. The investigators also exclude the patients where the placement of pneumatic cuff would be impossible (amputation, AV fistula)
Anesthesia procedure:
All the patients receive the same anesthesia technique, based on propofol and remifentanil at objective of concentration. Relaxation is achieved by cisatracurium in continuous infusion. This type of anesthesia is the current practice in Erasme hospital. All the patients are equipped with radial artery catheter and central venous catheter, the use of pulmonary artery catheter is left to anesthetist's discretion.
Before starting the CBP, all patients receive heparin with target ACT (activated clotting time) above 480seconds. The priming of CBP consists on 500ml of gelatin (Geloplasma, Fresenius), with 500ml of cristaloids (Plasmalyte, Baxter) and 200ml of mannitol (Mannitol 15%, Baxter). Cardioplegy is achieved by blood infusion (T 36°) with potassium chloride. The CBP flow is continuous of 2.4L/m2 and mean arterial pressure is maintened between 60 and 90 mm Hg. Glycemia is controlled strictly from the moment of anesthesia induction by short acting insulin administrered continuously.
All patients are transferred to ICU after the surgery, sedated with propofol and remifentanyl until hemodynamic stability and absence of bleeding is achieved. Sedation is then stopped and patient is extubated.
Vascular occlusion test:
Arterial diameter variation and Doppler flow are measured at brachial artery above medial epicondyl, proximally to the pneumatic cuff placed at forearm. For echography analysis, a linear probe of 12 MHz will be used, held by a metallic support to allow more precision and better reproducibility. After initial diameter measurement, pneumatic cuff 50 mmHg will be inflated above the arterial pressure of the patient during 5minutes, in order to induce ischemia. Diameter variations in brachial artery are measured continuously from 30 secondes before releasing of the cuff until 3 minutes afterwards. FMD is evaluated by following parameters : baseline diameter and maximal FMD variation in pourcents. In numerous studies, FMD is calculated using the formula: FMD (%) = ([diametre of maximal dilation after cuff release - baseline diametre]/ baseline diametre) x 100. In order to reduce variability of the measrure, diameter variation will be adjusted to baseline diameter and to initiating stimulus assessed by Doppler flow. Data will be stocked and analyzed by Quipu FMD.
StO2 is measured by tissular spectrometer (Invos, Covidien) consisting of a photodetector, processor and a 15 mm optic probe. This proble is placed over thenar eminence of the arm without any IV line. StO2 is enregistered every 2 secondes.
Practically, after performing the initial echographic measurements, and after 3 minutes of stabilisation of StO2 (baseline), an ischemic event of 5 minutes is created by a fast pneumatic cuff inflation to a value of 50mmHg above patients systemic blood pressure. This will stop arterial and venous blood flow in the forearm, leading to a decrease of HbO2 (= rate of decrease StO2 (%/s)).
After 5 minutes the cuff will be rapidly deflated (<1seconds) inducing arterial diameter and flow increase - the variation is assessed by echography and Doppler. At the same time, StO2 increases (= StO2 increase rate (%/s)) and achieves higher values than baseline (= reactive hyperemia = delta diametre, flow velocity and StO2). The NIRS device measures also THi (tissular hemoglobin index) at baseline and 1 minute, its minimum et maximum.
The increase rate of arterial diameter reflects endothelial reactivity while StO2 increase rate is considered as a tissue = hemoglobin flow marker. Reactive hyperemia can be interpreted as a test of microcirculation reactivity. Rate of StO2 decrease/THi is considered as oxygen consumption marker.
Syndecan-1 analysis is performed on frozen plasma by ELISA technique, using specific antibodies (ELISA kit from Ray Biotech, Inc), this method has already been used in previous studies.
Timing of measurements:
Measures are performed on the day before surgery, at the ICU admission, at 24h and at the day 7 of hospital stay.
Glycocalyx function assessment:
The first analysis will be performed on the day before surgery, then after anesthesia induction, at ICU admission, at 24h and 48h.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Solu - Medrol | Active comparator | Drug: Solu-medrol or placebo administrationSolu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration |
| Placebo | Placebo comparator | Drug: Solu-medrol or placebo administrationNaCl 0,9% 100ml IV once single administration |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- All patients eligible for cardiac surgery
Key exclusion criteria (4 listed)
- Age under 18years
- Allergy to corticoids
- Extreme emergency surgery
- Upper member vascular disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Solu-medrol or placebo administrationAlso: Solu-medrol 500mg IV BE145214, Solu-medrol 500mg IV H02AB04, Solu-medrol 500mg IV SUB14562MIG, Solu-medrol 500mg IV 277S102F12patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction | Drug | Placebo, Solu - Medrol |
Primary outcome
Flow Mediated Vasodilation change
Time frame: 3 measurements of 5 minutes each - vascular occlusion test once daily during 48h.
Arterial diameter variation and Doppler flow are measured at brachial artery during vascular occlusion test - viariation of diameter and doppler flow befor and after cuff release will be assessed
1 secondary outcome
StO2 variation change
Time frame: 4 measurements of 5 minutes each - vascular occlusion test test once daily during 48h
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2024.
- Background: PubMed 17126112Patila T, Kukkonen S, Vento A, Pettila V, Suojaranta-Ylinen R. Relation of the Sequential Organ Failure Assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg. 2006 Dec;82(6):2072-8. doi: 10.1016/j.athoracsur.2006.06.025.
- Background: PubMed 9315800Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997 Sep;112(3):676-92. doi: 10.1378/chest.112.3.676.
- Background: PubMed 8596232Riddington DW, Venkatesh B, Boivin CM, Bonser RS, Elliott TS, Marshall T, Mountford PJ, Bion JF. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA. 1996 Apr 3;275(13):1007-12.
- Background: PubMed 9485239Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg. 1998 Feb;65(2):420-4. doi: 10.1016/s0003-4975(97)01127-2.
- Background: PubMed 19054695Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):384-93. doi: 10.1053/j.jvca.2008.09.007. Epub 2008 Dec 3. No abstract available.
- Background: PubMed 18664462Whitlock RP, Chan S, Devereaux PJ, Sun J, Rubens FD, Thorlund K, Teoh KH. Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J. 2008 Nov;29(21):2592-600. doi: 10.1093/eurheartj/ehn333. Epub 2008 Jul 28.
- Background: PubMed 20537923Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J Cardiothorac Vasc Anesth. 2011 Feb;25(1):156-65. doi: 10.1053/j.jvca.2010.03.015. Epub 2010 May 26.
- Background: PubMed 26460660Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum A, Quantz M, Tagarakis GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S; SIRS Investigators. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Sep 26;386(10000):1243-1253. doi: 10.1016/S0140-6736(15)00273-1.
- Background: PubMed 26319483van Osch D, Dieleman JM, Nathoe HM, Boasson MP, Kluin J, Bunge JJ, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, de Lange F, Boer C, van Dijk D; Dexamethasone for Cardiac Surgery Study Group. Intraoperative High-Dose Dexamethasone in Cardiac Surgery and the Risk of Rethoracotomy. Ann Thorac Surg. 2015 Dec;100(6):2237-42. doi: 10.1016/j.athoracsur.2015.06.025. Epub 2015 Aug 25.
- Background: PubMed 19853081De Backer D, Dubois MJ, Schmartz D, Koch M, Ducart A, Barvais L, Vincent JL. Microcirculatory alterations in cardiac surgery: effects of cardiopulmonary bypass and anesthesia. Ann Thorac Surg. 2009 Nov;88(5):1396-403. doi: 10.1016/j.athoracsur.2009.07.002.
- Background: PubMed 25406739Alley H, Owens CD, Gasper WJ, Grenon SM. Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. J Vis Exp. 2014 Oct 22;(92):e52070. doi: 10.3791/52070.
- Background: PubMed 11788217Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65. doi: 10.1016/s0735-1097(01)01746-6.
- Individual participant dataSharing planned: No
Related trials for C.Surgical Procedure
Active, not recruiting
Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.
C.Surgical Procedure; Cardiac
Recruiting
Use of Stratafix Symmetric™ to Prevent Incisional Hernia in Gastrointestinal and Abdominal Surgery
C.Surgical Procedure; Disruption of Wound, Suture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luc Van Obbergh, Pr study chair
Anesthesia Department Hôpital Erasme
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study of C.Surgical Procedure and Cardiac, run by Erasme University Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 1 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Flow Mediated Vasodilation change (time frame: 3 measurements of 5 minutes each - vascular occlusion test once daily during 48h.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02798068, which also lists 27 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2024.